Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases

Wednesday, September 27, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has received a U.S. patent allowance for its PBGENE-PMM product, aimed at treating m.3243-associated mitochondrial diseases. This development highlights the company's innovative use of its proprietary ARCUS platform for advanced gene editing therapies. The patent is a significant milestone for Precision BioSciences as it continues to advance its therapeutic offerings.
Price reaction · baseline $11.319 (2023-09-26 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
-1.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences received a U.S. patent allowance.
  • The patent covers PBGENE-PMM for mitochondrial diseases.
  • The ARCUS platform is recognized for its innovative gene editing capabilities.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Sep. 27, 2023– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,

Frequently Asked Questions

What is PBGENE-PMM?

PBGENE-PMM is a product developed by Precision BioSciences targeting m.3243-associated mitochondrial diseases.

What technology does Precision BioSciences use?

Precision BioSciences utilizes its proprietary ARCUS platform for advanced gene editing therapies.

What recent achievement did Precision BioSciences announce?

Precision BioSciences announced the receipt of a U.S. patent allowance for PBGENE-PMM.

What is the significance of the U.S. patent allowance?

The U.S. patent allowance is a significant milestone for Precision BioSciences, enhancing its therapeutic offerings.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences PBGENE-PMM mitochondrial diseases gene editing ARCUS platform
Last updated: Sep 27, 2023

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →